BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 28856092)

  • 1. Comparison of [
    Lowe VJ; Lundt E; Knopman D; Senjem ML; Gunter JL; Schwarz CG; Kemp BJ; Jack CR; Petersen RC
    Neuroimage Clin; 2017; 16():295-302. PubMed ID: 28856092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
    Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Pittsburgh Compound-B Accumulation in the Subcortical White Matter of Alzheimer's Disease Brain.
    Wakabayashi Y; Ishii K; Hosokawa C; Hyodo T; Kaida H; Yamada M; Yagyu Y; Tsurusaki M; Kozuka T; Sugimura K; Murakami T
    Kobe J Med Sci; 2017 Mar; 62(5):E136-E141. PubMed ID: 28289271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White Matter Reference Region in PET Studies of
    Lowe VJ; Lundt ES; Senjem ML; Schwarz CG; Min HK; Przybelski SA; Kantarci K; Knopman D; Petersen RC; Jack CR
    J Nucl Med; 2018 Oct; 59(10):1583-1589. PubMed ID: 29674420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of
    Zeydan B; Schwarz CG; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
    J Nucl Med; 2022 Aug; 63(8):1239-1244. PubMed ID: 34916245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
    Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T;
    Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.
    Rowe CC; Pejoska S; Mulligan RS; Jones G; Chan JG; Svensson S; Cselényi Z; Masters CL; Villemagne VL
    J Nucl Med; 2013 Jun; 54(6):880-6. PubMed ID: 23575995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Gray-White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea.
    Ylä-Herttuala S; Hakulinen M; Poutiainen P; Lötjönen J; Könönen M; Gröhn H; Vanninen R; Mussalo H; Laitinen T; Mervaala E
    J Prev Alzheimers Dis; 2022; 9(3):499-506. PubMed ID: 35841251
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Higashi T; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Okina T; Suzuki N; Hasegawa H; Nagahama Y; Ishizu K; Oishi N; Kimura H; Watanabe H; Ono M; Saji H; Yamauchi H
    Ann Nucl Med; 2018 Apr; 32(3):206-216. PubMed ID: 29388083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers.
    Landau SM; Thomas BA; Thurfjell L; Schmidt M; Margolin R; Mintun M; Pontecorvo M; Baker SL; Jagust WJ;
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1398-407. PubMed ID: 24647577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
    Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in gray and white matter
    Son HJ; Oh JS; Roh JH; Seo SW; Oh M; Lee SJ; Oh SJ; Kim JS
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):357-366. PubMed ID: 30109402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.